You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥石科技(300725.SZ):2020年淨利升21.13%至1.84億元 擬10轉3派1元
格隆匯 03-25 19:43

格隆匯3月25日丨藥石科技(300725.SZ)披露2020年年度報吿,實現營業收入10.22億元,同比增長54.36%;歸屬於上市公司股東的淨利潤1.84億元,同比增長21.13%;歸屬於上市公司股東的扣除非經常性損益的淨利潤1.74億元,同比增長26.77%;基本每股收益1.29元,擬向全體股東每10股派發現金紅利1元(含税),以資本公積金向全體股東每10股轉增3股。

報吿期內公司進一步明確了以分子砌塊為核心資源,通過提供藥物發現解決方案、藥物開發和生產服務,結合創新化學和工程技術平台,全程助力新藥研發及商業化的業務發展戰略。基於此戰略,公司優化組織架構,組建分子砌塊、藥物發現和藥物開發和生產(CDMO)三大事業部,強化化學和工程技術中心、質量中心、供應鏈中心、EHS中心、銷售中心和子公司的建設,吸引了更多優秀高端人才的加入,為進一步打造世界一流團隊奠定基礎。公司營業收入水平及盈利規模進一步提升,新業務發展潛力強勁,經營能力進一步強化。

為保留和激勵核心人才,2019年公司實施了限制性股票激勵計劃,報吿期內股權激勵計劃實施增加公司管理費4858.65萬元。由於公司的主要收入來自海外客户,且主要以美元等外幣定價和結算,報吿期內因人民幣兑美元匯率的波動,公司增加匯兑損失2364.40萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account